.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,704,993

« Back to Dashboard

Details for Patent: 7,704,993

Title:Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
Abstract: The present invention relates to certain 1-substituted-2,3,4,5-tetrahydro-3-benzazepine derivatives of Formula (I), that are modulators of the 5HT2C receptor. Accordingly, compounds of the present invention are useful for the prophylaxis or treatment of 5HT2C receptor associated diseases, conditions or disorders, such as, obesity and related disorders.
Inventor(s): Smith; Brian (San Diego, CA), Gilson, III; Charles A. (San Diego, CA), Schultz; Jeffrey (San Diego, CA), Smith; Jeffrey (San Diego, CA)
Assignee: Arena Pharmaceuticals, Inc. (San Diego, CA)
Filing Date:Jun 16, 2004
Application Number:10/561,071
Claims:1. A compound of Formula (I): ##STR00032## wherein: R.sub.1 is H or C.sub.1-8 alkyl; R.sub.2 is C.sub.1-4 alkyl, --CH.sub.2--O--C.sub.1-4 alkyl, C.sub.1-4 haloalkyl or CH.sub.2OH; and R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are each independently H, C.sub.1-4 alkyl, amino, cyano,halogen, C.sub.1-4 haloalkyl, nitro or OH; or a pharmaceutically acceptable salt thereof; provided that when R.sub.2 is C.sub.1-4 alkyl, --CH.sub.2--O--C.sub.1-4 alkyl, or CH.sub.2OH then R.sub.3 and R.sub.6 are not both hydrogen.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R.sub.1 is H.

3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R.sub.1 is C.sub.1-8 alkyl.

4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R.sub.2 is C.sub.1-4 alkyl.

5. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R.sub.2 is methyl.

6. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R.sub.2 is C.sub.1-4 haloalkyl.

7. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R.sub.3 is H.

8. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R.sub.3 is C.sub.1-4 alkyl.

9. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R.sub.3 is halogen.

10. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R.sub.3 is C.sub.1-4 haloalkyl.

11. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R.sub.4 is H.

12. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R.sub.4 is C.sub.1-4 alkyl.

13. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R.sub.4 is halogen.

14. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R.sub.4 is C.sub.1-4 haloalkyl.

15. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R.sub.5 is H.

16. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R.sub.5 is C.sub.1-4 alkyl.

17. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R.sub.5 is halogen.

18. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R.sub.5 is C.sub.1-4 haloalkyl.

19. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R.sub.6 is H.

20. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R.sub.6 is C.sub.1-4 alkyl.

21. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R.sub.6 is halogen.

22. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R.sub.6 is C.sub.1-4 haloalkyl.

23. The compound of claim 1 selected from: 6,8-Dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine; 6-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine; 8-Chloro-9-fluoro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine; and 8,9-Dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine; or a pharmaceutically acceptable salt thereof.

24. The compound of claim 1 that is 9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine; or a pharmaceutically acceptable salt thereof.

25. The compound of claim 1 selected from: N-methyl-8,9-dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine; and N-methyl-9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine; or a pharmaceutically acceptable salt thereof.

26. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein said compound is an R enantiomer.

27. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein said compound is an S enantiomer.

28. A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

29. A method of treatment of a disorder selected from Male erectile dysfunction, and obesity, comprising administering to an individual in need of such treatment a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

30. The method according to claim 29 wherein the disorder is obesity.

31. The method according to claim 29 wherein the disorder is Male erectile dysfunction.

32. The method according to claim 30 or 31 wherein said individual is a human.

33. A method of decreasing food intake of an individual comprising administering to said individual a therapeutically effective amount of a compound according to claim 1, or a pharmaceutical acceptable salt thereof.

34. The method according to claim 33 wherein said individual is a human.

35. A method of inducing satiety in an individual comprising administering to said individual a therapeutically effective amount of a compound according to claim 1, or a pharmaceutical acceptable salt thereof.

36. The method according to claim 35 wherein said individual is a human.

37. A method of controlling weight gain of an individual comprising administering to said individual suffering from weight control a therapeutically effective amount of a compound according to claim 1, or a pharmaceutical acceptable salt thereof.

38. The method according to claim 37 wherein said individual is a human.

39. A method of producing a pharmaceutical composition comprising admixing at least one compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

40. The compound according to claim 1, or a pharmaceuttically acceptable salt thereof, wherein: R.sub.1 is H, methyl, ethyl, n-propyl, iso-propyl or n-butyl; R.sub.2 is methyl, ethyl, iso-propyl, n-butyl or --CF.sub.3; R.sub.3 is H, --CH.sub.3, amino, cyano, fluorine atom, chlorine atom, bromine atom, iodine atom, CF.sub.3, nitro or --OH; R.sub.4 is H, --CH.sub.3, amino, cyano, fluorine atom, chlorine atom, bromine atom, iodine atom, CF.sub.3, nitro or --OH; R.sub.5 is H, --CH.sub.3, amino, cyano, fluorine atom, chlorine atom, bromine atom, iodine atom, CF.sub.3, nitro or --OH; and R.sub.6 is H, --CH.sub.3, amino, cyano, fluorine atom, chlorine atom, bromine atom, iodine atom, CF.sub.3, nitro or --OH.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc